Glucose concentrations in enterally fed preterm infants

Alejandra Barrero-Castillero1,2,3, Wenyang Mao4, Ann R Stark4,5

  • 1Division of Newborn Medicine, Children's Hospital Boston, Boston, MA, USA. abcastil@bidmc.harvard.edu.

Insights

Hypoglycemia is common in preterm infants on enteral nutrition. The Pediatric Endocrine Society (PES) guideline increased glucose monitoring, but this may lead to unnecessary interventions in well-appearing infants.

Area of Science:

  • Neonatalogy
  • Pediatric Endocrinology
  • Clinical Nutrition

Background:

  • Neonatal hypoglycemia is a significant concern.
  • Current guidelines aim to maintain target glucose concentrations in preterm infants.
  • The impact of these guidelines on monitoring practices needs evaluation.

Purpose of the Study:

  • To determine the prevalence of glucose concentrations below 70 mg/dL in preterm infants on full enteral nutrition.
  • To assess the effect of the Pediatric Endocrine Society (PES) guideline on glucose monitoring practices.

Main Methods:

  • Retrospective cohort study of 1717 preterm infants.
  • Analysis of glucose concentrations at least 48 hours after parenteral fluid discontinuation.
  • Multivariate analysis to identify factors associated with low glucose levels.

Main Results:

  • 76.6% of glucose measurements were ≥70 mg/dL; 16.2% were 60-69 mg/dL; 5.9% were 50-59 mg/dL; 1.3% were <50 mg/dL.
  • Lower glucose concentrations (<60 mg/dL) were associated with male sex, lower postnatal age, small-for-gestational age, and maternal hypertension.
  • Glucose monitoring increased after the PES guideline implementation.

Conclusions:

  • Glucose concentrations below 70 mg/dL are frequent in preterm infants on enteral nutrition.
  • Increased monitoring post-guideline may lead to interventions without proven long-term benefits for well-appearing infants.
  • Re-evaluation of the PES threshold for this population may be warranted.
Abstract

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
26.9K
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
34.2K
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.5K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
674